Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.63 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19107899 | 0.97 | ACHE (0.68) | ACHEEPHX1EPHX2 | |
| SCHEMBL19107903 | 0.97 | ACHE (0.68) | ACHEEPHX1EPHX2 | |
| SCHEMBL16526224 | 0.91 | ACHE (0.76) | ACHEEPHX1 | |
| SCHEMBL15132643 | 0.91 | ACHE (0.76) | ACHEEPHX1 | |
| SCHEMBL11989433 | 0.91 | ACHE (0.76) | ACHEEPHX1 | |
| SCHEMBL10789983 | 0.89 | ACHE (0.79) | ACHEEPHX1EPHX2 | |
| SCHEMBL28158857 | 0.89 | ACHE (0.72) | ACHEEPHX1EPHX2 | |
| SCHEMBL10599960 | 0.89 | ACHE (0.79) | ACHEEPHX1EPHX2 | |
| SCHEMBL10299548 | 0.87 | ACHE (0.71) | ACHEEPHX1EPHX2 | |
| SCHEMBL13700220 | 0.87 | ACHE (0.75) | ACHEEPHX1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466122-B2 | Trialkyl cationic lipids and methods of use thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-06-18 | — | — | US | disclosed |
| US-20120172411-A1 | NOVEL TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172411-A1 | NOVEL TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF | NPC1L1, LDLR, CETP | ACHE 4843/4885EPHX1 3974/4885EPHX2 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.